Inoperable Head and Neck Cancer: A Historic Increase in Event-Free Survival with Pembrolizumab

Cancers arising in the head and neck affect vital structures such as the pharynx, larynx, oral cavity, and base of the tongue. At diagnosis, approximately 60–70% of patients have locally advanced disease: it has spread locally but has not produced distant metastases. At this stage, the tumor has invaded surrounding tissues and generally cannot be completely removed surgically. In particular, when a tumor is close to critical blood vessels and nerves, or the patient's general health does not permit surgery, the disease is described as “inoperable.” The mainstay of treatment is chemoradiotherapy (CRT), which combines chemotherapy and radiotherapy. However, CRT has limited effectiveness, and disease recurs or progresses over time in approximately half of patients.

Hope After 20 Years in Head and Neck Cancer: The Effect of Pembrolizumab in KEYNOTE-412

Immunotherapies that activate the immune system offer hope in this setting. Presented at ASCO 2025 as abstract 6013 , KEYNOTE-412 reported findings that could represent a breakthrough.

🔬 KEYNOTE-412 Study Summary

• Patient Population: Adults with newly diagnosed, inoperable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

• Number of Participants: 804 patients (402 in each arm)

• Design: Phase 3, randomized, double-blind, multinational clinical trial

• Treatment Protocols:

  • Intervention Arm: 17 cycles of pembrolizumab (200 mg, Q3W) + chemoradiotherapy (70 Gy radiotherapy + 3 cycles of cisplatin 100 mg/m² Q3W)

  • Control Arm: Placebo + the same CRT protocol

📊 Clinical Efficacy Findings

🔹 What Does the PD-L1 Biomarker Tell Us?

The PD-L1 level, which reflects the immune system's response to cancer, is important in predicting treatment response. In patients with PD-L1 CPS ≥1, the EFS benefit of pembrolizumab + CRT was more pronounced:

• Median EFS: 70.9 months (vs. 48.3 months)

• HR: 0.80 (95% CI: 0.64–0.98)

Adverse Effects and Long-Term Safety

• Serious adverse effects were at levels similar to earlier analyses.

• No “new” safety signal was identified.

• ❤️ Development of secondary cancers:

  • Pembrolizumab arm: 9%

  • Placebo arm: 11.2%

🔍 Clinical Meaning and Future Perspectives

For the first time, KEYNOTE-412 showed that adding immunotherapy to CRT may provide a multiyear benefit in patients with inoperable, locally advanced head and neck cancer. This finding offers new hope for a patient population whose standard treatments have remained unchanged for approximately 20 years.

New-generation studies will confirm the applicability of this approach in broader patient populations and its long-term effectiveness. For now, however, KEYNOTE-412 may stand at the threshold of a new era in head and neck cancer treatment.